Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses

Nakano, Kenji; Sato, Yukiko; Sasaki, Takeshi; Shimbashi, Wataru; Fukushima, Hirofumi; Yonekawa, Hiroyuki; Mitani, Hiroki; Kawabata, Kazuyoshi; Takahashi, Shunji

doi:10.3109/00016489.2016.1170876

Cited by 57 publications

(40 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 6 of 10 patients receiving targeted therapy responded (4 PRs, 2 complete responses) and 2 patients achieved durable stable disease, comprising a response rate of 60% and disease control rate of 80%. These findings compared favorably with response rates previously described …”

Section: Discussionsupporting

confidence: 86%

“…The approach to the incurable recurrent or metastatic patient is unclear, due to the great biological heterogeneity, which is highly histology‐dependent. Responses to systemic agents in unselected patients are generally modest . As randomized controlled studies are lacking, treatment selection in SGCs should be made on a more personalized approach.…”

Section: Introductionmentioning

confidence: 99%

“…Salivary duct carcinoma (SDC) is an aggressive tumor with high likelihood of distant metastasis. A carboplatin‐paclitaxel doublet achieved an impressive response rate of 39% . Antiangiogenic agents have also been explored in SDC and MEC, and in a phase II trial, sorafenib achieved a 22% response rate …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience

et al. 2019

View full text Add to dashboard Cite

Background Salivary gland cancers (SGCs) are rare. The approach to metastatic patients is histology‐dependent. There is little evidence on whether next‐generation sequencing (NGS) findings translate to tumor control in SGCs. Methods We analyzed all patients with histologically confirmed SGC who underwent NGS. Results Twenty‐seven patients were identified, 14 (51.8%) had targetable findings in NGS: 5 ERBB2 amplifications, 3 PIK3CA mutations, 2 RUNX1 mutations, 1 TRIM33‐RET fusion, 1 FGFR3‐TACC3 fusion, 1 microsatellite instability‐high, and 2 high mutational burden. Ten patients were treated accordingly. Median progression‐free survival for targeted treatment was 8.4 months. Of five patients who achieved durable responses of 8.4 to 31.3 months, two are ongoing. The overall median survival was not reached for patients receiving targeted treatment and was 40.4 months for patients treated conventionally (P = .18). Conclusions In the absence of a well‐established therapeutic approach, NGS may detect clinically significant genetic alterations and benefit patients with advanced SGC.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In a retrospective series of 18 patients with salivary duct carcinoma treated with carboplatin and paclitaxel, they had a median PFS of 6.5 months and median OS of 34.7 months. 16 In case of HER2-positive salivary duct carcinoma, which is observed in 21%-44% of patients with salivary duct carcinoma, trastuzumab may be added to chemotherapy. 17,18 In fact, trastuzumab-based treatment regimens have shown some promising responses.…”

Section: Discussionmentioning

confidence: 99%

Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands

et al. 2017

View full text Add to dashboard Cite

BackgroundSalivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor‐positive. Only limited data are available on androgen deprivation therapy (ADT).MethodsPatients with advanced androgen receptor‐positive salivary duct carcinoma treated with first‐line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression‐free survival [PFS] and overall survival [OS]). The OS was compared with patients with advanced salivary duct carcinoma who received best supportive care.ResultsThirty‐four of 35 patients who were ADT‐treated were evaluable: 6 patients had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the ADT‐treated patients was 4 months and the median duration of clinical benefit was 11 months. The median OS was 17 months versus 5 months in 43 patients receiving best supportive care (P = .02).ConclusionWe recommend ADT in advanced androgen receptor‐positive salivary duct carcinoma given its response and clinical benefit. © 2017 Wiley Periodicals, Inc. Head Neck, 2017

show abstract

“…5 In contrast, a recent retrospective review of patients with SDC suggested a benefit to treatment with combined carboplatin and paclitaxel. 6 Notably, this cohort of 18 patients was established from a retrospective review of >8 years of clinical records, which exemplifies the difficulty of performing robust prospective clinical trials in this type of cancer. A larger retrospective evaluation of 495 patients with SDC listed in the National Cancer Database indicated that surgical resection was superior to all other modalities, with insufficient data available to properly evaluate the role of conventional or targeted chemotherapies.…”

Section: Discussionmentioning

confidence: 99%

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition

Lin¹,

Nabell²,

Spencer³

et al. 2018

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Salivary duct carcinoma (SDC) is a rare and aggressive malignancy for which limited data exist to guide treatment decisions. With the advent of advanced molecular testing and tumor genomic profiling, clinicians now have the ability to identify potential therapeutic targets in difficult-to-treat cancers such as SDC. This report presents a male patient with widely metastatic SDC found on targeted next-generation sequencing to have a BRAF p.V600E mutation. He experienced a prolonged and robust response to first-line systemic chemotherapy with dabrafenib and trametinib. During his response interval, new data emerged to justify subsequent treatment with both an immune checkpoint inhibitor and androgen blockade after his disease progressed. To our knowledge, this is the first report of frontline BRAF-directed therapy eliciting a response in metastatic SDC.

show abstract

Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses

Abstract: Salivary gland cancer patients showed a moderate clinical response to the combination chemotherapy of carboplatin and paclitaxel. The objective response rates differed according to the pathological diagnoses, but there were no significant differences in prognoses.

Cited by 57 publications

References 15 publications

Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience

Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience

Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition

Contact Info

Product

Resources

About